Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 959 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Arm 1- Dose Escalation Clear all

Conditions: Obstructive Sleep Apnea, Sleep-disordered Breathing
Interventions: Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition, Placebo; placebo comparator condition; Other · Device · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 79 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: B-Cell Chronic Lymphocytic Leukemia
Interventions: FluCAM [Fludara + Campath], fludarabine phosphate; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Progressive Metastatic Castrate Resistant Prostate Cancer
Interventions: Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD, Tulmimetostat Doses 1 or 2 QD, Tulmimetostat RP2D QD, JSB462 Dose 1 QD, JSB462 Dose 2 QD, JSB462 QD, Standard of Care (SoC); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 8
States / cities: Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 5 more

Conditions: Healthy
Interventions: PRA023, Placebo; Drug · Other
Lead sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Laboratory Biomarker Analysis, Leflunomide, Pharmacological Study; Other · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Duarte, California

Conditions: Cancer
Interventions: BMS-906024; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 6
States / cities: Los Angeles, California • Atlanta, Georgia • Detroit, Michigan + 3 more

Conditions: Metastatic Colorectal Cancer (MCRC)
Interventions: Cetuximab, Irinotecan, Brivanib, Brivanib Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: Los Angeles, California • Louisville, Kentucky • St Louis, Missouri

Conditions: Healthy
Interventions: nikkomycin Z; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 40 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Neoplasms, Malignant
Interventions: cabazitaxel, gemcitabine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Detroit, Michigan • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more

Conditions: Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Interventions: Iberdomide, Carfilzomib, Daratumumab, Dexamethasone, Acetaminophen, Diphenhydramine, Montelukast; Drug
Lead sponsor: Benjamin T Diamond, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Brain Tumor, Astrocytoma, Astroglioma, Glioblastoma, Gliosarcoma
Interventions: Zotiraciclib (TG02), Temozolomide (TMZ); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Germinal Center B-cell Type (GCB)
Interventions: Rituximab, Etoposide, Copanlisib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, ECHO, EKG, MRI Brain, 18F-FDG - PET, CT Scan, Bone Marrow Aspiration, Bone Marrow Biopsy, Lumbar Puncture (LP); Biological · Drug · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Myeloma
Interventions: Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg, Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg, Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg, Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg, Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Oleclumab, Osimertinib, AZD4635; Biological · Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 101 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 9
States / cities: La Jolla, California • San Francisco, California • Aurora, Colorado + 6 more

Conditions: Advanced Solid Cancer
Interventions: ORB-011; Drug
Lead sponsor: Orionis Biosciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Scottsdale, Arizona • Houston, Texas

Conditions: Healthy
Interventions: PF-04965842, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cancer, Pancreatic Cancer, Pancreatic Carcinoma
Interventions: CPI-613, Gemcitabine; Drug
Lead sponsor: Cornerstone Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 2
States / cities: The Bronx, New York • Dallas, Texas

Conditions: Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
Interventions: FX-909, Pembrolizumab (KEYTRUDA ®), KEYTRUDA ®( Pembrolizumab); Drug
Lead sponsor: Flare Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: San Francisco, California • New Haven, Connecticut • Miami, Florida + 7 more

Conditions: Sanfilippo Syndrome, Mucopolysaccharidosis III
Interventions: Epidiolex, Placebo; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 4 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Torrance, California

Conditions: Plasma Cell Myeloma Refractory
Interventions: Isatuximab, Dexamethasone, Pomalidomide, Belantamab mafodotin, Pegenzileukin, SAR439459, Belumosudil, Evorpacept; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more

Conditions: Adenoid Cystic Carcinoma
Interventions: AG-013736 (AXITINIB); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: CC-122, Ibrutinib, Obinutuzumab; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 8
States / cities: La Jolla, California • Boston, Massachusetts • Hackensack, New Jersey + 5 more

Conditions: Opioid Use Disorder, Opioid Withdrawal, Substance Use Disorders
Interventions: Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo, Matching Intramuscular Placebo, My-E-Health SENTINEL Digital Monitoring and Human-Gated Escalation Platform, Standardized Psychological Preparation, Integration and Recovery Support, Garmin-Enabled Longitudinal Wellness Monitoring; Drug · Device · Behavioral + 1 more
Lead sponsor: Clive Michelsen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Basalt, Colorado

Conditions: Influenza
Interventions: Influenza Virus Quadrivalent Inactivated Vaccine, Sodium Chloride, 0.9%, VRC-FLUNPF099-00-VP (H1ssF_3928); Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea

Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

A Study of PRA023 in Healthy Volunteers

Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma

Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors

Phase I/II Combination With Irinotecan- Erbitux

Safety and PK of Nikkomycin Z in Healthy Subjects

Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Dasatinib in Combination With Revlimid (and Dexamethasone)

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

ORB-011 In Patients With Advanced Solid Tumors

First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects

A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

Study of Cannabidiol in Sanfilippo Syndrome

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma

A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults